Printer Friendly

ENDOGEN, INC. ANNOUNCES THIRD QUARTER RESULTS

 BOSTON, April 30 /PRNewswire/ -- Endogen, Inc. (OTC: ENDG) announced today that revenues for the nine months ended Feb. 28, 1993 increased to $1,804,006 from $1,307,881 in the comparable period last year, an increase of 38 percent. Revenues, which are derived entirely from product sales, increased primarily as a result of continued strong demand for Endogen's expanding product lines. Net income for the nine months was $128,868, or three cents per share vs. a loss of $210,179 or (30 cents) per share in the comparable period a year ago.
 "I am pleased with the substantial increase in Endogen's revenues," commented Owen A. Dempsey, president and CEO of Endogen. "With the substantial increase in our cash reserves as a result of the previously announced acquisition of Diagnostics Holding Corp., we believe Endogen is well positioned for the future."
 Endogen, Inc. is a leading developer, manufacturer and supplier of specialty research products and immuno-assay test kits to the growing biomedical research market. The company's products are used by researchers who are investigating cytokines, adhesion molecules, and other components of the immune system. Endogen currently markets over 120 research products and 17 immuno-assay kits worldwide.
 ENDOGEN, INC.
 Unaudited Condensed Statement of Operations
 Three Months Ended Nine Months Ended
 2/28/93 2/29/92 2/28/93 2/29/92
 Revenue:
 Product sales $614,269 $540,341 $1,804,006 $1,307,881
 Costs & Expenses:
 Cost of sales 206,359 231,285 562,862 535,735
 Selling & marketing 113,865 93,904 337,118 265,644
 General & admin. 136,493 108,380 401,862 412,959
 Research & develop. 138,917 104,721 364,954 300,707
 Income (loss) from
 operations 18,635 2,051 137,210 (207,164)
 Interest expense 2,456 2,496 8,342 3,015
 Net income (loss) 16,179 (445) 128,868 (210,179)
 Net income
 per share(a) (1 cent) (3 cents) 3 cents (30 cents)
 Weighted average
 shares outstanding 991,797 988,446 1,742,244 988,446
 Proforma earnings per
 calculation at Feb. 28,
 1993 to reflect the
 subsequent acquisition
 of Diagnostics Holding
 Corp:
 Pro forma net income
 per share 1 cent --- 7 cents ---
 Pro forma weighted
 avg. shares
 outstanding 1,742,244 --- 1,742,244 ---


NOTE (a): Net income of $16,179 for the three months ended Feb. 28, 1993, or negative earnings per share of (1 cent) reflects accretion of Preferred Stock dividends of $27,853. Upon consummation of the acquisition of Diagnostics Holding Corp., the Preferred Stock converted into Common Stock basis and the preferred Stock accretion was reversed.
 -0- 4/30/93
 /CONTACT: Owen A. Dempsey, president and CEO of Endogen, 617-439-3250/
 (ENDG)


CO: Endogen, Inc. ST: Massachusetts IN: MTC SU: ERN

DJ -- NE008 -- 3239 04/30/93 13:13 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 30, 1993
Words:464
Previous Article:WTC INDUSTRIES, INC. ANNOUNCES SENIOR MANAGEMENT RESTRUCTURING
Next Article:TRAK AUTO CORPORATION ANNOUNCES RESTRUCTURING CHARGE IMPACTS EARNINGS
Topics:


Related Articles
MEDAMICUS ANNOUNCES THIRD QUARTER RESULTS
ENDOGEN, INC. RAISES $3.075 MILLION
ENDOGEN, INC. ANNOUNCES YEAR-END RESULTS
ENDOGEN, INC. ANNOUNCES FIRST QUARTER RESULTS
ENDOGEN, INC. ANNOUNCES FIRST QUARTER RESULTS
ENDOGEN, INC. ANNOUNCES SECOND QUARTER RESULTS
ENDOGEN, INC. ANNOUNCES THIRD QUARTER FINANCIAL RESULTS
Endogen, Inc. Announces First Quarter Financial Results
Endogen, Inc. Announces Strong Second Quarter Results
Endogen Announces Launch of mRNA Detection Kits

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters